* Q4 EPS $0.13 beats Street by 8 cents
* Revenue rises 50 pct to $53.8 mln
* Backs 2010 revenue view of $235 mln to $255 mln
* Shares up 3 pct in after-hours trade
March 4 (Reuters) - Emergent BioSolutions Inc (EBS.N) posted a better-than-expected quarterly profit on higher sales of its anthrax vaccine, BioThrax, and backed its 2010 revenue outlook, sending its shares up 3 percent in extended trade.
For the fourth quarter, the company reported a net income of $4.2 million, or 13 cents a share, compared with $1.5 million, or 5 cents a share, a year ago.
Revenue rose 50 percent to $53.8 million.
Analysts on average expected earnings of 5 cents a share, excluding special items, on revenue of $51.7 million, according to Thomson Reuters I/B/E/S.
The company backed its 2010 revenue forecast of $235 million to $255 million.
Analysts on average were expecting revenue of $230.2 million for the year.
Shares of the company were up 41 cents at $15.34 in after-hours trade. They closed at $14.93 Thursday on the New York Stock Exchange. (Reporting by Anand Basu in Bangalore; Editing by Ratul Ray Chaudhuri)